Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response

The Journal of Infectious Diseases
T AllanderM A Persson

Abstract

The antibody response to the hypervariable region of the E2 protein (HVR1) of hepatitis C virus (HCV) was studied in 5 patients who were infected by a common virus strain during an outbreak in a hemodialysis unit. Two patients resolved the infection, while 3 developed chronic HCV infection. For studying the antibody response to HVR1 during the early phase of infection, a Western blot assay using recombinant phage displaying HVR1 was developed. The 2 patients with resolving infection had a more rapid antibody response to HVR1 than did the patients developing chronic infection. Anti-HVR1 antibodies were repeatedly absent in 1 of the chronically infected patients. Antibodies to recombinant E2 protein occurred later than the anti-HVR1 antibodies and did not correlate with resolution of the infection. Thus, the present results suggest that early appearance of antibodies to the HVR1 may predict clearance of HCV infection.

Citations

Oct 26, 2002·Journal of Hepatology·Xavier FornsRobert H Purcell
Mar 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jean-Christophe MeunierJens Bukh
Nov 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Birke BartoschRobert H Purcell
Jul 16, 2008·Clinics in Liver Disease·Zania StamatakiJane A McKeating
Jun 2, 1998·Rheumatic Diseases Clinics of North America·R W McMurray
Nov 1, 2001·Clinics in Liver Disease·P Farci
Mar 4, 2014·Antiviral Research·Jonathan K BallJane A McKeating
May 26, 2001·The American Journal of Gastroenterology·N FurusyoS Kashiwagi
Jun 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tae-Hwe HeoChang-Yuil Kang
Apr 29, 2020·Cold Spring Harbor Perspectives in Medicine·Mansun Law

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.